Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Kezar Life Sciences ( (KZR) ).
On March 30, 2026, Kezar Life Sciences agreed to be acquired by Aurinia Pharmaceuticals in a cash-and-CVR transaction structured as a tender offer and follow-on merger. Aurinia will pay $6.955 per Kezar share in cash plus a non-transferable contingent value right, with closing targeted for the second quarter of 2026 and backed by a support agreement from 9% holder Tang Capital Partners.
The deal gives Aurinia control of zetomipzomib, Kezar’s first-in-class immunoproteasome inhibitor that has shown promising Phase 2 results in autoimmune hepatitis, strengthening Aurinia’s autoimmune pipeline while Kezar shareholders gain immediate liquidity and potential upside from future monetization. CVR holders stand to share in any excess closing net cash over $50 million and in future proceeds tied to zetomipzomib, Kezar’s Everest collaboration, and the sale of its Sec61 platform to Enodia, underscoring a structured wind-down of Kezar’s standalone operations with ongoing economic participation for investors.
The most recent analyst rating on (KZR) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Kezar Life Sciences stock, see the KZR Stock Forecast page.
Spark’s Take on KZR Stock
According to Spark, TipRanks’ AI Analyst, KZR is a Neutral.
The score is held down primarily by weak financial fundamentals (continued losses, negative cash flow, and equity erosion) and bearish technical signals. A modest offset comes from the recent strategic divestiture that improves focus and preserves potential milestone/royalty upside, but valuation is difficult to support given ongoing losses and no dividend.
To see Spark’s full report on KZR stock, click here.
More about Kezar Life Sciences
Kezar Life Sciences is a South San Francisco–based clinical-stage biopharmaceutical company developing novel small-molecule therapeutics for immune-mediated diseases and cancer. Its lead asset, zetomipzomib, a selective immunoproteasome inhibitor, is in mid-stage development for autoimmune hepatitis and has potential applications across multiple chronic autoimmune conditions.
Aurinia Pharmaceuticals, headquartered in Rockville and Edmonton, is a biopharmaceutical group focused on autoimmune diseases with high unmet medical need. It commercializes LUPKYNIS, the first FDA-approved oral therapy for adult patients with active lupus nephritis, and is advancing aritinercept, a dual BAFF/APRIL inhibitor, for additional autoimmune indications.
Average Trading Volume: 36,765
Technical Sentiment Signal: Hold
Current Market Cap: $45.4M
See more insights into KZR stock on TipRanks’ Stock Analysis page.